These include blinatumomab (a CD19/CD3 BSAB) for treating B-ALL, epcoritamab (a CD20/CD3 BSAB) for R/R DLBCL, mosunetuzumab (a CD20/CD3 BSAB) for FL, teclistamab (a BCMA/CD3 BSAB) for MM, amivantamab (an EGFR/cMET BSAB) for NSCLC with EGFR ex20ins mutations, and cadonilimab (AK104, PD-1/CTLA-4 BSABs) for recurrent/metastatic cervical cancer. This evidence concerns the gene PDCD1 and acute lymphoblastic leukemia.